To date, the utility of immunohistochemistry (IHC) markers has not been established in DCIS diagnostics, in contrast to IBC, where the hormone receptors (HRs) for estrogen (ER) and progesterone (PR), HER2, and Ki67 proliferation index are all deciding on a complex treatment algorithm. Here, MKI67 is linked to ductal breast carcinoma in situ.